280 related articles for article (PubMed ID: 28317081)
1. Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.
Maxwell RR; Cole PD
Curr Hematol Malig Rep; 2017 Jun; 12(3):176-186. PubMed ID: 28317081
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol.
Aslam S; Ameer S; Shabana NA; Ahmed M
Sci Rep; 2021 Dec; 11(1):23757. PubMed ID: 34887513
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Gutierrez-Camino A; Bilbao-Aldaiturriaga N; Pombar-Gomez M; Martin-Guerrero I; Garcia-Orad A
Pharmacogenomics; 2014 Jul; 15(10):1383-98. PubMed ID: 25155938
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.
Franca R; Rebora P; Bertorello N; Fagioli F; Conter V; Biondi A; Colombini A; Micalizzi C; Zecca M; Parasole R; Petruzziello F; Basso G; Putti MC; Locatelli F; d'Adamo P; Valsecchi MG; Decorti G; Rabusin M
Pharmacogenomics J; 2017 Jan; 17(1):4-10. PubMed ID: 26644204
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.
Davidsen ML; Dalhoff K; Schmiegelow K
J Pediatr Hematol Oncol; 2008 Nov; 30(11):831-49. PubMed ID: 18989161
[TBL] [Abstract][Full Text] [Related]
6. Grade 3 and 4 Toxicity Profiles During Therapy of Childhood Acute Lymphoblastic Leukemia.
Zawitkowska J; Lejman M; Zaucha-Prażmo A; Drabko K; Płonowski M; Bulsa J; Romiszewski M; Mizia-Malarz A; Kołtan A; Derwich K; Karolczyk G; Ociepa T; Ćwiklińska M; Trelińska J; Owoc-Lempach J; Niedźwiecki M; Kiermasz A; Kowalczyk J
In Vivo; 2019; 33(4):1333-1339. PubMed ID: 31280227
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of acute lymphoblastic leukemia treatment response.
Cunningham L; Aplenc R
Expert Opin Pharmacother; 2007 Oct; 8(15):2519-31. PubMed ID: 17931087
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
Levinsen M; Rotevatn EØ; Rosthøj S; Nersting J; Abrahamsson J; Appell ML; Bergan S; Bechensteen AG; Harila-Saari A; Heyman M; Jonsson OG; Maxild JB; Niemi M; Söderhäll S; Schmiegelow K;
Pediatr Blood Cancer; 2014 May; 61(5):797-802. PubMed ID: 24395436
[TBL] [Abstract][Full Text] [Related]
9. The influence of polymorphisms in the drug transporter, ABCB1 on the toxicity of glucocorticoids in Saudi children with acute lymphoblastic leukaemia.
ElFayoumi RI; Hagras MM; Abozenadaha A; Gari M; Abosoudah I; Shinawi T; Mirza T; Bawazir W
Pharmacol Rep; 2019 Feb; 71(1):90-95. PubMed ID: 30508724
[TBL] [Abstract][Full Text] [Related]
10. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia.
Aldoss I; Douer D
Blood; 2020 Mar; 135(13):987-995. PubMed ID: 31977001
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
Stocco G; Crews KR; Evans WE
Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.
van den Akker-van Marle ME; Gurwitz D; Detmar SB; Enzing CM; Hopkins MM; Gutierrez de Mesa E; Ibarreta D
Pharmacogenomics; 2006 Jul; 7(5):783-92. PubMed ID: 16886902
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics of childhood acute lymphoblastic leukemia.
Brenner TL; Pui CH; Evan WE
Curr Opin Mol Ther; 2001 Dec; 3(6):567-78. PubMed ID: 11804271
[TBL] [Abstract][Full Text] [Related]
14. Impact of DARC, GSDMA and CXCL2 polymorphisms on induction toxicity in children with acute lymphoblastic leukemia: A complementary study.
Gatineau-Sailliant S; Glisovic S; Gagné V; Laverdière C; Leclerc JM; Silverman LB; Sinnett D; Krajinovic M; Pastore Y
Leuk Res; 2019 Nov; 86():106228. PubMed ID: 31590117
[No Abstract] [Full Text] [Related]
15. Pharmacogenetics in acute lymphoblastic leukemia.
Cheok MH; Pottier N; Kager L; Evans WE
Semin Hematol; 2009 Jan; 46(1):39-51. PubMed ID: 19100367
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system chemotoxicity during treatment of pediatric acute lymphoblastic leukemia/lymphoma.
Vagace JM; de la Maya MD; Caceres-Marzal C; Gonzalez de Murillo S; Gervasini G
Crit Rev Oncol Hematol; 2012 Nov; 84(2):274-86. PubMed ID: 22578745
[TBL] [Abstract][Full Text] [Related]
17. Thiopurine S-methyltransferase pharmacogenetics in childhood acute lymphoblastic leukemia.
Yang JJ; Bhojwani D
Methods Mol Biol; 2013; 999():273-84. PubMed ID: 23666706
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of acute lymphoblastic leukemia.
Kager L; Evans WE
Curr Opin Hematol; 2006 Jul; 13(4):260-5. PubMed ID: 16755223
[TBL] [Abstract][Full Text] [Related]
19. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.
Cheok MH; Evans WE
Nat Rev Cancer; 2006 Feb; 6(2):117-29. PubMed ID: 16491071
[TBL] [Abstract][Full Text] [Related]
20. Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics.
Lennard L; Cartwright CS; Wade R; Vora A
Br J Haematol; 2015 Apr; 169(2):228-40. PubMed ID: 25441457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
